US SEC Trading Suspension Halt Orders — April 22, 2026

22-04-2026

EON Resources Inc. received a notice of noncompliance from NYSE American on April 16, 2026, for failing to timely file its Form 10-K for the year ended December 31, 2025, by the April 15, 2026 deadline, due to ongoing delays in financial reporting and close procedures. The company has an Initial Cure Period until October 15, 2026, to file the report and regain compliance, with no immediate effect on the listing of its Class A Common Stock (EONR) or redeemable warrants (EONR WS), though delisting proceedings could commence if unresolved. While the company expects to file within the cure period, no assurances are provided, highlighting significant compliance risks amid its operations of 20,000 Permian Basin acres with 750 wells producing over 1,000 barrels of oil per day.

• ·Form 12b-25 for late filing was submitted on April 1, 2026.
• ·Potential additional six-month cure period beyond October 15, 2026, at NYSE American's discretion.
• ·Grayburg-Jackson Field features stacked pay zones from 1,500-4,000 feet depth; South Justis Field from 5,000-7,000 feet.

22-04-2026

Vivos Therapeutics, Inc. received a Nasdaq notice on April 17, 2026, indicating failure to meet the $2.5M minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), with reported negative equity of approximately $1.55M as of December 31, 2025. The company raised $6.8M in aggregate gross proceeds during Q1 2026 via a $4.6M warrant exercise and $2.25M private placement to address the deficiency, but these do not fully cure it. The company has until June 1, 2026, to submit a compliance plan, with possible extension to October 14, 2026, though delisting remains a material risk if unsuccessful.

• ·No immediate impact on the listing or trading of VVOS common stock on Nasdaq
• ·Compliance plan submission deadline: June 1, 2026; potential extension through October 14, 2026
• ·Delisting would have a material adverse effect on the company, its operations, and reputation

22-04-2026

Greenwave Technology Solutions, Inc. received a Nasdaq notice on April 20, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to file its Form 10-K for the fiscal year ended December 31, 2025. The company has 60 calendar days to submit a compliance plan, with potential extension up to 180 days until October 12, 2026, if accepted. While trading of GWAV common stock continues uninterrupted on the Nasdaq Capital Market, there is heightened risk of delisting if compliance is not regained.

• ·Notification disclosed in accordance with Nasdaq Listing Rule 5810(b).
• ·Press release issued on April 22, 2026, attached as Exhibit 99.1.
• ·Forward-looking statements highlight risks including no assurance of regaining compliance or avoiding delisting.

22-04-2026

Graf Global Corp. received a notice from NYSE American on April 16, 2026, stating non-compliance with Section 1007 of the NYSE American Company Guide due to failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025. The notice has no immediate effect on trading but risks delisting if not cured within the six-month period from the Annual Report's due date, with a possible additional six-month extension subject to NYSE American approval. The Company is working to file the report as soon as practicable.

• ·Form 12b-25 filed on April 1, 2026, disclosing need for additional time to file 10-K
• ·Previous 10-K for year ended December 31, 2024, filed on March 13, 2025
• ·Cure period: six months from Annual Report due date, with possible further six-month extension request
• ·Press release issued on April 22, 2026 (Exhibit 99.1)

22-04-2026

Apimeds Pharmaceuticals US, Inc. received a notice from NYSE Regulation on April 17, 2026, stating non-compliance with continued listing requirements under Section 1007 of the NYSE American Listed Company Manual due to failure to timely file its Form 10-K for the fiscal year ended December 31, 2025. The company has an initial six-month cure period from April 17, 2026, to file the 10-K and regain compliance, with a possible additional six-month extension; it expects to file by April 30, 2026, but provides no assurance of meeting this date. The common stock continues to trade under ticker APUS with a '.LF' late filing designation, but the trading halt initiated on April 2, 2026, remains in effect.

• ·Securities registered: Common Stock, par value $0.01 per share, ticker APUS on NYSE American LLC
• ·Emerging growth company: Yes
• ·Form 12b-25 filed with SEC on March 31, 2025, disclosing delay reasons related to financial statement preparation and audit completion
• ·Press release issued April 22, 2026 (Exhibit 99.1)

22-04-2026

BIO-key International, Inc. received a notice from Nasdaq on April 16, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-K for the fiscal year ended December 31, 2025. The notification has no immediate effect on the listing or trading of the company's common stock (BKYI) on the Nasdaq Capital Market. The company issued a press release on April 22, 2026, regarding the matter.

• ·Non-compliance with Nasdaq Listing Rule 5250(c)(1), requiring timely filing of periodic financial reports with the SEC
• ·Securities registered: Common Stock (BKYI) on Nasdaq Capital Market
• ·Company address: 101 Crawfords Corner Road Suite 4116, Holmdel, NJ 07733; Phone: (732) 359-1100

22-04-2026

Tevogen Bio Holdings Inc. received Nasdaq notices on April 16 and 17, 2026, for failing the $50 million minimum market value of listed securities (Rule 5450(b)(2)(A)) and $15 million minimum market value of publicly held shares (Rule 5450(b)(2&3)(C)) over 30 consecutive business days. The company has 180 calendar days to comply, until October 13, 2026 (MVLS) and October 14, 2026 (MVPHS), by achieving the thresholds for 10-20 consecutive business days. No immediate delisting effect, but the company may consider options like transferring to Nasdaq Capital Market with no assurance of success.

• ·Notifications based on review of prior 30 consecutive business days.
• ·Emerging growth company status confirmed.
• ·Principal executive offices: 15 Independence Boulevard, Suite #210, Warren, New Jersey 07059.

22-04-2026

La Rosa Holdings Corp. (LRHC) received a Nasdaq notice on April 16, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to file its Form 10-K for the fiscal year ended December 31, 2025. The company has 60 days (until June 15, 2026) to submit a compliance plan, with potential extension up to 180 days (October 12, 2026), but faces delisting risk if unresolved, with no immediate impact on its Nasdaq listing. The company intends to file the 10-K promptly but provides no assurances of success.

• ·Nasdaq will consider the company's past compliance history, reasons for late filing, financial condition, and public disclosures when reviewing any compliance plan.
• ·Company operates a full-service escrow settlement and title company in Florida.
• ·Expansion into Europe has begun with Spain.